---
title: "Bank of America Securities Sticks to Their Buy Rating for Stevanato Group (STVN)"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/269722920.md"
description: "Bank of America Securities analyst Michael Ryskin reiterated a Buy rating for Stevanato Group, setting a price target of $30.00. Ryskin, a 4-star analyst with a 4.2% average return, covers the Healthcare sector. The analyst consensus for Stevanato Group is a Moderate Buy with an average price target of $27.00."
datetime: "2025-12-15T13:05:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269722920.md)
  - [en](https://longbridge.com/en/news/269722920.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269722920.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/269722920.md) | [繁體中文](https://longbridge.com/zh-HK/news/269722920.md)


# Bank of America Securities Sticks to Their Buy Rating for Stevanato Group (STVN)

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Stevanato Group today and set a price target of $30.00.

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

According to TipRanks, Ryskin is a 4-star analyst with an average return of 4.2% and a 56.40% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Illumina, Thermo Fisher, and Elanco Animal Health.

Currently, the analyst consensus on Stevanato Group is a Moderate Buy with an average price target of $27.00.

### 相关股票

- [Stevanato Group SpA (STVN.US)](https://longbridge.com/zh-CN/quote/STVN.US.md)

## 相关资讯与研究

- [Stevanato Group Earnings Call Highlights High-Value Surge](https://longbridge.com/zh-CN/news/278237276.md)
- [Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/zh-CN/news/281183048.md)
- [LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)](https://longbridge.com/zh-CN/news/280882703.md)
- [Advantage Energy Ltd. (OTCMKTS:AAVVF) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/zh-CN/news/280981094.md)
- [Idorsia Ltd (IDIA) Receives a Rating Update from a Top Analyst](https://longbridge.com/zh-CN/news/281283879.md)